UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 0810, 2026

BIOAGE LABS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-42279	47-4721157
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5885 Hollis Street Suite 370
Emeryville, California		94608
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 510 806-1445

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 Par Value Per Share	BIOA	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207 ResultsSubmission of OperationsMatters andto Financiala ConditionVote of Security Holders.

On ~~May~~June 810, 2026, BioAge Labs, Inc. (the “Company”) ~~issued~~held ~~a press release announcing~~ its ~~financial results for the first quarter ended March 31,~~ 2026. AAnnual ~~copy~~Meeting of ~~the~~Stockholders ~~press~~and ~~release~~the isCompany’s ~~attached~~stockholders asvoted ~~Exhibit~~on ~~99.1~~and toapproved ~~this~~the ~~Current~~following ~~Report on Form 8-K.~~proposals:

The ~~information~~election inof ~~this~~three ~~Item~~Class ~~2.02~~II Directors, ~~including~~Patrick ~~Exhibit~~Enright, 99M.1B.A., ~~attached~~James toI. ~~this~~Healy, ~~report~~M.D., ~~shall~~Ph.D., ~~not~~and beRekha ~~deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934~~Hemrajani, ~~as amended (the “Exchange Act”)~~M.B.A., oreach ~~otherwise subject~~ to ~~the~~serve ~~liabilities of that section or Sections 11 and 12(~~a~~)(2)~~ ofthree-year ~~the~~term, ~~Securities~~which ~~Act~~will ofexpire ~~1933,~~at ~~as amended (~~the ~~“Securities~~2029 ~~Act”).~~Annual ~~The~~Meeting ~~information~~of ~~contained~~Stockholders ~~in this Item 2.02~~ and inuntil ~~the~~such ~~accompanying~~time ~~Exhibit~~as ~~99.1~~their ~~shall~~respective ~~not~~successors behave ~~incorporated~~been byduly ~~reference~~elected ~~into~~and ~~any~~qualified ~~other~~or ~~filing~~until ~~under~~such ~~the~~director’s ~~Exchange~~earlier ~~Act~~resignation or ~~under~~removal. ~~the~~The ~~Securities~~vote ~~Act,~~tally ~~except~~was as ~~shall be expressly set forth by specific reference in such filing.~~follows:

Item 9.01 Financial Statements and Exhibits.


Nominees	Shares For	Shares Withheld	Broker Non-Votes
Patrick Enright, M.B.A.	30,075,928	1,184,271	5,327,405
James I. Healy, M.D., Ph.D.	25,499,205	5,760,994	5,327,405
Rekha Hemrajani, M.B.A.	27,826,781	3,433,418	5,327,405

~~(d) Exhibits~~The ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The vote tally was as follows:

ExhibitNo.		Description
Shares For	Shares Against	Shares Abstaining
99.1		Press release issued by BioAge Labs, Inc. dated May 8, 2026.
36,561,171	1,305	25,128
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BIOAGE LABS, INC.
Date:	~~May~~June 812, 2026	By:	/s/ Dov Goldstein
			Dov Goldstein, M.D.Cheif Financial Officer
			Dov Goldstein, M.D.Chief Financial Officer

Filing Compare · BioAge Labs, Inc.